Drug Safety
- All
- News
- Videos
-
Drug Regulator Tightens Watch On GLP-1 Weight-Loss Drugs, Issues Notice
The Central Drugs Standard Control Organization, along with state regulators, has initiated targeted enforcement measures to curb malpractices and ensure ethical pharmaceutical practices in the supply chain.
-
Safety Checks For New Generic Weight-Loss Drugs To Be Increased: Government
New Delhi, March 24 (IANS) Amid serious concerns over recent introduction of multiple generic variants of GLP-1 based weight loss drugs in the Indian market, the government on Tuesday said it has intensified regulatory surveillance against the drug’s
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
Weight-loss Drugs Linked To Preterm Birth Risk In Women With Pre-Existing Diabetes
The research analysed data from more than 750,000 pregnancies, making it one of the largest studies to examine this issue so far.
-
Affordable Semaglutide Is Coming: Should You Be Worried About Drug Safety, Health Risks And Side Effects?
India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.
-
From Diabetes To Weight Loss: How Semaglutide Became The Blockbuster Behind Ozempic, Wegovy
From a diabetes drug to a global weight-loss phenomenon, semaglutide has reshaped modern medicine. As patents expire, cheaper versions may expand access, raising questions about affordability, safety and long-term impact.
-
What Happens If You Stop Taking Antibiotics In The Middle Of A Course?
It is important that you complete the full course of your antibiotics as it reduces side effects like nausea or allergic reactions and chances of reinfection. However, a lot of people don't adhere to your medications, which can impact your health.
-
The Lancet Reports A Boom In Fake Obesity Drugs: What You Need To Know
A new Lancet report pinpoints that a boom in counterfeit obesity drugs is taking place. Here is what you need to know about the dangers that these drugs pose and why following the properly established medical guidance is key to being safe.
-
Food And Drug Safety Measures Reinforced In Gujarat With Surat's New High-Tech Lab
The Gujarat government is expanding its network of laboratories across the state to ensure citizens have access to pure food and quality medicines, Health Minister Praful Pansheriya said in the state Assembly on Thu
-
India Cracks Down On Ads For Weight-Loss Drugs Like GLP-1 In New Advisory
India's Health Ministry has warned pharmaceutical firms against promoting GLP-1 weight-loss drugs to the public. The CDSCO says direct or indirect advertising, including influencer campaigns, violates drug laws and could attract regulatory action.
-
Drug Regulator Tightens Watch On GLP-1 Weight-Loss Drugs, Issues Notice
The Central Drugs Standard Control Organization, along with state regulators, has initiated targeted enforcement measures to curb malpractices and ensure ethical pharmaceutical practices in the supply chain.
-
Safety Checks For New Generic Weight-Loss Drugs To Be Increased: Government
New Delhi, March 24 (IANS) Amid serious concerns over recent introduction of multiple generic variants of GLP-1 based weight loss drugs in the Indian market, the government on Tuesday said it has intensified regulatory surveillance against the drug’s
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
Weight-loss Drugs Linked To Preterm Birth Risk In Women With Pre-Existing Diabetes
The research analysed data from more than 750,000 pregnancies, making it one of the largest studies to examine this issue so far.
-
Affordable Semaglutide Is Coming: Should You Be Worried About Drug Safety, Health Risks And Side Effects?
India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.
-
From Diabetes To Weight Loss: How Semaglutide Became The Blockbuster Behind Ozempic, Wegovy
From a diabetes drug to a global weight-loss phenomenon, semaglutide has reshaped modern medicine. As patents expire, cheaper versions may expand access, raising questions about affordability, safety and long-term impact.
-
What Happens If You Stop Taking Antibiotics In The Middle Of A Course?
It is important that you complete the full course of your antibiotics as it reduces side effects like nausea or allergic reactions and chances of reinfection. However, a lot of people don't adhere to your medications, which can impact your health.
-
The Lancet Reports A Boom In Fake Obesity Drugs: What You Need To Know
A new Lancet report pinpoints that a boom in counterfeit obesity drugs is taking place. Here is what you need to know about the dangers that these drugs pose and why following the properly established medical guidance is key to being safe.
-
Food And Drug Safety Measures Reinforced In Gujarat With Surat's New High-Tech Lab
The Gujarat government is expanding its network of laboratories across the state to ensure citizens have access to pure food and quality medicines, Health Minister Praful Pansheriya said in the state Assembly on Thu
-
India Cracks Down On Ads For Weight-Loss Drugs Like GLP-1 In New Advisory
India's Health Ministry has warned pharmaceutical firms against promoting GLP-1 weight-loss drugs to the public. The CDSCO says direct or indirect advertising, including influencer campaigns, violates drug laws and could attract regulatory action.
